IP Library Patent Application 14958358
Patent Application
App. No. 14/958,358

CELL FUSION PROMOTER AND UTILIZATION OF THE SAME

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/958,358
Abstract

A regeneration promoter for regenerating tissue with the use of somatic stem cells is provided. Also provided are a cell fusion promoter comprising ATP or its metabolite which is safely usable in vivo, a method of producing fused cells in the presence of ATP or its metabolite and a related pharmaceutical composition for regenerating or improving the function of a tissue or an organ in a subject suffering from dysfunction or hypofunction due to injury or denaturation.

Claims (13)

1 - 40 . (canceled)

41 . A method of producing a fused cell in a subject in need of regeneration treatment, the method comprising:

administering to a subject in need of regeneration treatment a stem cell and ATP in an amount and at a concentration sufficient to cause the fusion of the stem cell and a somatic cell in the subject to regenerate or improve a cardiac cell, tissue or organ,

wherein said stem cell and said ATP are administered at a site where dysfunction or hypofunction occurs due to cardiac damage or degeneration.

42 . The method of claim 41 , wherein the stem cell is a somatic stem cell.

43 . The method of claim 42 , wherein the somatic stem cell is a bone marrow cell.

44 . The method of claim 41 , wherein the somatic cell is a myocardial cell.

45 . The method of claim 41 , wherein the stem cell is an autologous cell.

46 . The method of claim 41 , wherein said cardiac damage or degeneration is ischemic heart disease due to heart failure.

47 . The method of claim 46 , wherein the heart failure is attributable to heart infarction.

48 . The method of claim 41 , wherein the concentration of ATP is between 1 mM-3 mM.

49 . The method of claim 41 , wherein the ATP is administered in a pharmaceutical composition comprising said ATP and a pharmaceutical carrier.

50 . The method of claim 41 , wherein the method further comprises administering a somatic cell.